Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.
Amélie MarsotRomain GuilhaumouCamille RiffOlivier BlinPublished in: Clinical pharmacokinetics (2017)
This review highlights the different population pharmacokinetic models for amikacin developed in critically ill patients over the past decades and proposes relevant information for clinicians and researchers. To optimize amikacin dosage, this review points out the relevant covariates according to the target population. In a population of critically ill patients, dose optimization mainly depends on creatinine clearance and total body weight. New pharmacokinetic population studies could be considered, with new covariates of interest to be tested in model building and to further explain variability. Another future perspective could be external evaluation of previously published models.